| Literature DB >> 31952199 |
Zaira F Kharaeva1, Magomet Sh Mustafaev2, Anzor V Khazhmetov2, Ismail H Gazaev3, Larisa Z Blieva1, Lukas Steiner4, Wolfgang Mayer5, Chiara De Luca5, Liudmila G Korkina6.
Abstract
OBJECTIVE: To distinguish clinical effects and mechanisms of sodium monofluorophosphate plus xylitol and herbal extracts of Swiss medicinal plants (Chamomilla recutita, Arnica montana, Echinacea purpurea, and Salvia officinalis).Entities:
Keywords: anti-bacterial effects; anti-inflammatory effects; bacerial catalase; gingival crevicular fluid; gingivitis; herbal extracts; interleukins; nitric oxide; periodontitis; total antioxidant activity
Year: 2020 PMID: 31952199 PMCID: PMC7148460 DOI: 10.3390/dj8010010
Source DB: PubMed Journal: Dent J (Basel) ISSN: 2304-6767
Demographic distribution of patients with gingivitis and the initial stage of periodontitis (PD) in the treatment groups.
| Group | Patients | Age, Years | Sex | Smokers | Diagnosis | ||
|---|---|---|---|---|---|---|---|
| M | F | Gingivitis | Initial PD | ||||
| Experimental (conventional treatment + ETP twice a day for 60 days) | 35 | 35–55 | 12 | 23 | 5 | 8 | 27 |
| Control (conventional treatment + CTP twice a day for 60 days) | 15 | 36–55 | 7 | 8 | 3 | 3 | 12 |
Figure 1Effects of experimental (ETP) and control toothpaste (CTP) on clinical markers of gingivitis and periodontitis. (A) Dynamics of the CPITN score in the experimental (EXP) and control (CTR) groups of patients. N-normal range of values obtained in healthy people. * p < 0.05 vs. baseline values; ** p < 0.05 vs. CTR. (B) Dynamics of the PMA index in the experimental (EXP) and control (CTR) groups of patients. N-normal range of values obtained in healthy people. # p < 0.01 vs. baseline values; ** p < 0.05 vs. CTR. (C) Dynamics of t hOHI-S score in the experimental (EXP) and control (CTR) groups of patients. N-normal range of values obtained in healthy people. (D) Dynamics of the gingival and plaque Sillness–Loe score in the experimental (EXP) and control (CTR) groups of patients. N-normal range of values obtained in healthy people. # p < 0.01 vs. baseline values; ## p < 0.01 vs. CTR.
Figure 2Effects of ETP and CTP on inflammatory cytokines in gingival crevicular fluid (GCF). (A) Dynamics of cytokine IL-1beta (pg/mL) in the experimental (EXP) and control (CTR) groups of patients. N: normal range of values obtained in healthy people. ** p < 0.01 vs. baseline values; # p < 0.05 vs. CTR. (B) Dynamics of cytokine IL-6 (pg/mL) in the experimental (EXP) and control (CTR) groups of patients. N: normal range of values obtained in healthy people. ** p < 0.01 vs. baseline values; # p < 0.05 vs. CTR. (C) Dynamics of cytokine IL-17A (pg/mL) in the experimental (EXP) and control (CTR) groups of patients. N: normal range of values obtained in healthy people. * p < 0.05 vs. baseline values; ** p < 0.01 vs. background values; ## p < 0.01 vs. CTR. (D) Dynamics of cytokine IL-10 (pg/mL) in the experimental (EXP) and control (CTR) groups of patients. N: normal range of values obtained in healthy people. ** p < 0.01 vs. baseline values; # p < 0.05 vs. CTR.
Figure 3Nitrite and nitrate (NO2−/NO3−) levels (μM) in gingival crevicular fluid in the experimental (EXP) and control (CTR) groups of patients before and after the trial. N: normal range of values obtained in healthy people. * p < 0.05 vs. baseline values; ** p < 0.01 vs. baseline values; ## p < 0.01 vs. CTR.
Figure 4Total antioxidant activity (AOA, %) in gingival crevicular fluid in the experimental (EXP) and control (CTR) groups of patients before and after the trial. N: normal range of values obtained in healthy people. * p < 0.05 vs. baseline values; ** p < 0.01 vs. baseline values; ## p < 0.01 vs. CTR.
Effects of ETP and CTP on the counts of high-risk and moderate-risk of periodontitis/gingivitis—inducing bacteria in the gingival crevicular fluid.
| Bacteria, Risk Grade | Experimental Group (n = 15) | Control Group (n = 5) | ||
|---|---|---|---|---|
| Before (Cells/mL) | After 2 Months (Cells/mL) | Before (Cells/mL) | After 2 Months (Cells/mL) | |
|
| 7.9 × 105 | 2.8 × 104 | 1.6 × 103 | 0 |
|
| 2.8 × 106 | 0 | 2.9 × 106 | 2.1 × 104 |
|
| 7.8 × 103 | 0 | 1.2 × 104 | 0 |
|
| 3.3 × 105 | 0 | 5.9 × 105 | 1.9 × 105 |
|
| 1.2 × 106 | 0 | 1.9 × 106 | 0 |
|
| 5.8 × 105 | 0 | 1.4 × 105 | 4.5 × 106 |
|
| 6.6 × 105 | 1.6 × 102 | 4.4 × 105 | 0 |
Direct anti-bacterial effects of ETP, CTP, and herbal actives of ETP and their action towards microbial catalase activity and intracellular microbial survival.
|
| |||
| Sample | Direct Anti-Bacterial Effect | Bacterial Catalase Activity after Pre-Treatment with Toothpaste/Herbal Extract | Number of Bacteria Survived in Phagocytes after Pre-Treatment, Cells/mL |
|---|---|---|---|
| Negative control (no pre-treatment) | 5 × 106 | 5.1 (0%) | 5 × 106 |
| Control toothpaste (CTP) | 105 | 4.5 (11.8%) | 5 × 105 |
| Experimental toothpaste (ETP) | 5 × 103 | 3.1 (39.2%) | 5 × 102 |
| Chamomile leaves extract | 106 | 2.7 (47.0%) | 104 |
| Salvia leaves extract | 106 | 1.9 (63.7%) | 102 |
| Arnica flower extract | 106 | 2.5 (50.9%) | 103 |
| Echinacea flower extract | 106 | 2.8 (54.9%) | 103 |
The sources and characteristics of S. aureus strains used in experiments on phagocytosis, intracellular killing, catalase-inhibiting, and anti-microbial activity of ETP and CTP.
| Strain Number | Source of Isolation | Resistance to 5–10 Antibiotics | Catalase Activity (Units/2 × 107 Bacteria) |
|---|---|---|---|
| 1523 | Throat, tonsils (chronic tonsillitis) | +++ |
|
| 1546 | Oral epithelia (stomatitis) | − |
|
| 1549 | Throat, tonsils (chronic tonsillitis) | ++ |
|
| 1555 | Oral epithelia (stomatitis) | + |
|
| 1561 | Nasal sinuses (sinusitis) | − |
|
| 1612 | Oral epithelia (stomatitis) | − |
|
| 1620 | Throat, tonsils (chronic tonsillitis) | + |
|
| 1643 | Throat, tonsils (chronic tonsillitis) | − |
|
| 1670 | Oral epithelia (stomatitis) | − |
|
| 1780 | Throat, tonsils (chronic tonsillitis) | − |
|
The in vitro effects of ETP, CTP, and active ingredients of ETP to catalase activity in S. aureus strains.
| Sample | Initial Catalase Activity | Catalase Activity (U/mL) in |
|---|---|---|
| Control toothpaste (CTP) | 2.38 ± 0.90 | 2.27 ± 0.93 |
| Experimental toothpaste (ETP) | 2.38 ± 0.90 | 1.52 ± 0.13 * |
| Chamomile leaves extract | 2.38 ± 0.90 | 1.81 ± 0.21 |
| Salvia leaves extract | 2.38 ± 0.90 | 1.28 ± 0.71 * |
| Arnica flower extract | 2.38 ± 0.90 | 1.68 ± 0.70 |
| Echinacea flower extract | 2.38 ± 0.90 | 1.27 ± 0.71 * |
| Mixture of extracts | 2.38 ± 0.90 | 1.51 ± 0.42 * |
* p < 0.05.
Figure 5Mechanisms underlying clinical effects of experimental and control toothpastes. Control toothpaste (CTP); experimental toothpaste (ETP).